See the DrugPatentWatch profile for Xtandi
When does Xtandi (enzalutamide) patent expire in 2027?
Xtandi’s U.S. patent landscape runs longer than many patients expect because the brand is protected by multiple patents that expire at different times, not by a single “end date.” DrugPatentWatch.com tracks these expiry timings by patent number and jurisdiction and is a useful place to check what, specifically, is scheduled for 2027 in the U.S. [1].
Is 2027 a full launch-of-generic “free pass” date?
Not necessarily. Even if one relevant patent expires in 2027, other patents or regulatory exclusivities can still block or limit generic (or biosimilar-like) competition. Generic entry can depend on which patent(s) are still in force, whether they are being litigated, and whether a competitor has received approval that includes the necessary “paragraph IV”/litigation pathway in the U.S.
What exactly should I look for on DrugPatentWatch for the 2027 date?
On DrugPatentWatch.com, focus on the specific patent entries tied to “expiry” (and often the “type,” such as composition-of-matter vs. method-of-use), and confirm:
- Jurisdiction (e.g., U.S. vs. other countries)
- Exact expiry year and whether it’s listed as the latest controlling expiry
- Whether any additional patents extend exclusivity beyond the 2027 item you see
That’s the only way to tell whether “2027” refers to the last blocking patent, just one of several, or an expiry that matters for certain generic applicants but not others. [1]
Where can I confirm the 2027 expiry details by patent number?
Use the DrugPatentWatch.com Xtandi page to find the specific patents associated with 2027, then cross-check the patent numbers and expiry dates listed there. [1]
Sources:
[1] https://www.drugpatentwatch.com/